Molecular Hydrogen Prevents Osteoclast Activation in a Glucocorticoid-Induced Osteoporosis Zebrafish Scale Model.
Marta Carnovali, Giuseppe Banfi, Massimo Mariotti · Antioxidants (Basel, Switzerland) · 2023
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In an animal model, an in vitro study performed on RAW264.7 murine cells showed that H₂ treatment prevents RANKL-associated osteoclastogenesis, inhibiting the inactivation of NF-kB, mitogen-activated protein kinase (MAPK) and AKT pathways. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water was evaluated in this publication and summarizes the source-grounded findings below. An in vitro study performed on RAW264.7 murine cells showed that H₂ treatment prevents RANKL-associated osteoclastogenesis, inhibiting the inactivation of NF-kB, mitogen-activated protein kinase (MAPK) and AKT pathways.
What the Researchers Studied
The study used a preclinical animal experiment. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 80 µM H₂ (≈0.161 mg/L); reported treatment duration: 14 days. An in vitro study performed on RAW264.7 murine cells showed that H₂ treatment prevents RANKL-associated osteoclastogenesis, inhibiting the inactivation of NF-kB, mitogen-activated protein kinase (MAPK) and AKT pathways.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The study used a preclinical animal experiment. The hydrogen delivery method was hydrogen-rich water. The source-reported hydrogen concentration was 80 µM H₂ (≈0.161 mg/L). The reported treatment duration was 14 days.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.